The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy.
10.1016/j.cjtee.2020.06.002
- VernacularTitle:The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy
- Author:
Hong-Yuan LIN
1
Author Information
1. Forth Medical Center, General Hospital of PLA, Beijing, China. Electronic address: hylin304@aliyun.com.
- Publication Type:Journal Article
- Keywords:
COVID-19;
Immunomodulatory therapy;
Immunotherapy;
Sepsis;
Thymosin a1;
Ulinastatin
- MeSH:
Adrenal Cortex Hormones;
therapeutic use;
Betacoronavirus;
Coronavirus Infections;
complications;
Glycoproteins;
therapeutic use;
Humans;
Immunologic Factors;
therapeutic use;
Pandemics;
Pneumonia, Viral;
complications;
Sepsis;
drug therapy;
etiology;
Thymalfasin;
therapeutic use
- From:
Chinese Journal of Traumatology
2020;23(4):190-195
- CountryChina
- Language:English
-
Abstract:
COVID-19 is known for its magical infectivity, fast transmission and high death toll based on the large number of infected people. From the perspective of the clinical manifestation, autopsy examination and pathophysiology, the essence of COVID-19 should be viewed as a sepsis induced by viral infection, and has the essential characteristics as sepsis induced by other pathogens. Therefore, in addition to etiological and supportive treatment, immunomodulatory therapy is also appropriate to severe COVID-19. Although there is still a lack of consensus on immunotherapy for sepsis so far, relatively rich experiences have been accumulated in the past decades, which will help us in the treatment of severe COVID-19. This article will elaborate immunotherapy of sepsis, though it may not be consistent.
